Posted by Michael Wonder on 25 Oct 2023
Annexon receives PRIME designation from the EMA for ANX007 for the treatment of geographic atrophy
24 October 2023 - PRIME designation granted based on Phase 2 ARCHER trial results, which showed meaningful preservation of visual function in patients with geographic atrophy.
Annexon today announced that the EMA has granted Priority Medicine (PRIME) designation to ANX007 for the treatment of geographic atrophy secondary to age-related macular degeneration.
